JAFRAL Participates in AMR Conference 2026 in Basel
This month, JAFRAL had the privilege of participating in the AMR Conference in Basel, one of the leading global events dedicated to tackling antimicrobial resistance (AMR).
The conference brought together innovators, researchers, industry leaders and policymakers with a shared mission: accelerating the development of novel solutions that can address the growing AMR crisis.
As Europe’s largest provider of high‑quality bacteriophage products for research, preclinical, and clinical applications, JAFRAL contributed to the discussion by highlighting the critical role of phage‑based therapeutics in the future AMR landscape. Our team presented insights on scalable phage manufacturing, quality control, and regulatory readiness—key aspects required to bring phage therapies closer to clinical and commercial use.
During the event, we also engaged in meaningful conversations with partners, biotech companies, and AMR-focused organizations about the potential of bacteriophages as a complementary or alternative approach to traditional antibiotics. With antibiotic resistance rising worldwide, bacteriophage therapy is increasingly recognized as a promising tool that can provide targeted, effective, and safe treatment against difficult-to-treat bacterial infections.
JAFRAL is proud to be part of the global AMR innovation ecosystem and remains committed to advancing bacteriophage manufacturing excellence. Our participation in the AMR Conference reflects our dedication to supporting cutting‑edge therapeutic development and contributing to solutions that can make a real impact on public health.
